Pahang Pharmacy
Concise Prescribing Info
Peripheral & central neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisation. Generalised anxiety disorder (GAD); fibromyalgia.
Dosage/Direction for Use
Neuropathic pain Initially 150 mg daily, may be increased to 300 mg daily after 3-7 days interval. Max: 600 mg daily after an additional 7-day interval. Fibromyalgia Initially 75 mg bd, may be increased to 150 mg bd w/in 1 wk or if needed, further increased to 225 mg bd. Max: 600 mg daily after an additional wk. Epilepsy Initially 150 mg daily, may be increased to 300 mg daily after 1 wk. Max: 600 mg daily after an additional wk. GAD Initially 150 mg daily, may be increased to 300 mg daily after 1 wk & 450 mg daily following an additional wk. Max: 600 mg daily after an additional wk. CrCl ≥60 mL/min Initially 150 mg daily bd or tds. Max: 600 mg daily, ≥30-<60 mL/min Initially 75 mg daily bd or tds. Max: 300 mg daily, ≥15-<30 mL/min Initially 25-50 mg once or bd. Max: 150 mg daily, <15 mL/min Initially 25 mg once daily. Max: 75 mg daily. Supplementary following haemodialysis 25 mg as single dose. Max: 100 mg daily.
May be taken with or without food.
Special Precautions
Discontinue use if hypersensitivity; life-threatening angioedema; diagnosed or suspected myopathy, markedly elevated creatine kinase levels occur. Increased risk of suicidal thoughts or behavior. Peripheral edema; CHF patients w/ NYHA class III or IV; dizziness, somnolence; loss of consciousness, confusion, mental impairment; wt gain; blurred vision; decreased platelet count; prolonged PR interval; encephalopathy. Evaluate patients for history & signs of drug abuse. Avoid abrupt or rapid discontinuation; taper-off gradually over min of 1 wk. Concomitant use w/ anti-spasticity agents. May affect ability to drive & use machines. Renal impairment. Women of childbearing potential should use effective contraception. Not to be used during pregnancy. Lactation. Not recommended in childn <12 yr & adolescents 12-17 yr. Elderly >65 yr.
Adverse Reactions
Dizziness, somnolence, headache. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, depression, disorientation, insomnia, decreased libido; ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, constipation, flatulence, abdominal distension, dry mouth, nausea, diarrhea; muscle cramp, arthralgia, back & limb pain, cervical spasm; peripheral oedema, oedema, abnormal gait, fall, feeling drunk & abnormal, fatigue; increased wt.
Drug Interactions
Potentiated ethanol & lorazepam effects. Resp failure & coma w/ other CNS depressants. Additive cognitive & gross motor function impairment w/ oxycodone. Reduced lower GI tract function w/ opioid analgesics.
MIMS Class
Anticonvulsants / Drugs for Neuropathic Pain
ATC Classification
N03AX16 - pregabalin ; Belongs to the class of other antiepileptics.
Rewisca hard cap 150 mg
6 × 10's
Rewisca hard cap 50 mg
6 × 10's
Rewisca hard cap 75 mg
6 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in